Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer

  • Tomoshi TsuchiyaEmail author
  • Keitaro Matsumoto
  • Takuro Miyazaki
  • Hiroyuki Yamaguchi
  • Takuya Yamazaki
  • Isao Sano
  • Junya Fukuoka
  • Yoichi Nakamura
  • Naoya Yamasaki
  • Takeshi Nagayasu
Original Article



Because chemoradiotherapy using cisplatin and S-1, an oral fluoropyrimidine, is effective for unresectable non-small cell lung cancer (NSCLC), an induction setting was used in a multicenter phase II study (Clinical trial number: UMIN000008205). The correlations of relapse and clinicopathological factors were analyzed.


We defined locally advanced NSCLC as pathologically proven chest wall invasion or hilar and/or mediastinal lymph node metastases by endobronchial ultrasound-guided transbronchial needle aspiration. The patients received two courses of S-1 administration for 14 days and intravenous cisplatin injection on day 8. A total dose of 40 Gy radiotherapy was concurrently received. Surgical resection was performed after completion of the treatment.


Of the 23 eligible patients, 18 had stage IIIA and 5 had stage IIB NSCLC. Twenty of the eligible patients (87.0%) completed the regimen. Six (26.1%) complete responses were identified and 12 cases (52.2%) were histopathologically downstaged by induction chemoradiotherapy (ICRT). The 3-year overall survival rate was 58.1% and relapse-free survival (RFS) rate was 52.0%, respectively. Among several clinicopathological parameters, univariate RFS analysis identified that only downstaging was significantly associated with longer RFS times (p = 0.003). The radiological response did not reflect pathological response. When the variables of preoperative pathologically proven N2 metastasis, pathological ICRT effectiveness, and downstaging were included in the Cox proportional hazard modes, only the parameter of downstaging displayed significant hazard ratio (hazard ratio 0.13, p = 0.010).


This protocol is considered an option among preoperative therapies and has obvious benefits for pathologically downstaged cases.

Clinical trial number


Trial registration date

June 19, 2012.


Induction chemoradiotherapy S-1 Relapse Downstaging Non-small cell lung cancer 



We wish to thank Dr. Sumihisa Honda and Dr. Shuntaro Sato for providing statistical advice. We also thank Dr. Mary Durbin for critical reading of the manuscript.


No funding was provided.

Compliance with ethical standards

Conflict of interest

The authors have nothing to disclosure with regard to commercial support. The authors have no conflicts of interest.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.CrossRefGoogle Scholar
  2. 2.
    Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.CrossRefGoogle Scholar
  3. 3.
    Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura KFM. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–57.CrossRefGoogle Scholar
  4. 4.
    Shirasaka T, Shimamoto Y, Fukushima M, Shi Y. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004–09.Google Scholar
  5. 5.
    Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001;85:939–43.CrossRefGoogle Scholar
  6. 6.
    Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004;10:7860–4.CrossRefGoogle Scholar
  7. 7.
    Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, et al. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer. 2009;101:225–31.CrossRefGoogle Scholar
  8. 8.
    Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, et al. A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Lung Cancer. 2015;87:141–47.CrossRefGoogle Scholar
  9. 9.
    Tsuchiya T, Nakamura Y, Hayashi N, Matsumoto K, Miyazaki T, Nakatomi K, et al. A multicenter phase II study of concurrent chemoradiotherapy with cisplatin and oral S-1, followed by surgery for locally advanced non-small-cell lung cancer. Cancer Treat Commun. 2016;7:11–6.CrossRefGoogle Scholar
  10. 10.
    Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefGoogle Scholar
  11. 11.
    Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.CrossRefGoogle Scholar
  12. 12.
    Caglar HB, Baldini EH, Othus M, Rabin MS. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer. 2009;115:4156–66.CrossRefGoogle Scholar
  13. 13.
    Taira N, Kawasaki H, Furugen T, Ichi T, Kushi K, Yohena T, et al. The long-term prognosis of induction chemotherapy followed by surgery for N2 non-small cell lung cancer: a retrospective case series study. Ann Med Surg. 2017;17:65–9.CrossRefGoogle Scholar
  14. 14.
    Robinson LA, Tanvetyanon T, Grubbs D, Antonia S, Creelan B, Fontaine J, et al. Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer. Lung Cancer. 2018;122:206–13.CrossRefGoogle Scholar
  15. 15.
    Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990;8:911–34.CrossRefGoogle Scholar
  16. 16.
    Lawrence TS, Blackstock W, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 2003;13:13–21.CrossRefGoogle Scholar
  17. 17.
    Naida JD, Davis MA, Lawrence TS. The effect of activation of wild-type p53 function on fluoropyrimidine-mediated radiosensitization. Int J Radiat Oncol Biol Phys. 1998;41:675–80.CrossRefGoogle Scholar
  18. 18.
    Takagi M, Sakata KI, Someya M, Tauchi H, Iijima K, Matsumoto Y, et al. Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol. 2010;96:259–66.CrossRefGoogle Scholar
  19. 19.
    Schwartz GN, Teicher B, Eder JP, Korbut T, Holden S, Ara G, et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacot. 1993;32:167–72.CrossRefGoogle Scholar
  20. 20.
    Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA. 1986;83:8923–25.CrossRefGoogle Scholar
  21. 21.
    Yamamoto N, Yamanaka T, Ichinose Y, Kubota K, Sakai H, Gemma A, et al. Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type. Anticancer Res. 2010;30:2985–90.Google Scholar
  22. 22.
    Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286–91.Google Scholar
  23. 23.
    Tsuchiya T, Arai J, Matsumoto K, Miyazaki T, Honda S, Tagawa T, et al. Prognostic Impact of the ABCC11/MRP8 polymorphism in adjuvant oral chemotherapy with S-1 for non-small cell lung cancer. Chemotherapy. 2016;61:77–86.CrossRefGoogle Scholar
  24. 24.
    Jeremić B, Casas F, Dubinsky P, Gomez-Caamano A, Čihorić N, Videtic G, et al. Treatment-related predictive and prognostic factors in trimodality approach in stage IIIA/N2 non-small cell lung cancer. Front Oncol. 2018;8:30. (eCollection).CrossRefGoogle Scholar
  25. 25.
    Phernambucq ECJ, Spoelstra FOB, Paul M, Senan S, Melissant CF, Postmus PE, et al. Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancer. Eur J Cardiothorac Surg. 2009;36:1052–57.CrossRefGoogle Scholar
  26. 26.
    Shintani Y, Funakoshi Y, Inoue M, Takeuchi Y, Okumura M, Maeda H, et al. Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2012;18:530–35.CrossRefGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2019

Authors and Affiliations

  • Tomoshi Tsuchiya
    • 1
    • 7
    Email author
  • Keitaro Matsumoto
    • 1
  • Takuro Miyazaki
    • 1
  • Hiroyuki Yamaguchi
    • 2
  • Takuya Yamazaki
    • 3
  • Isao Sano
    • 4
  • Junya Fukuoka
    • 5
  • Yoichi Nakamura
    • 6
  • Naoya Yamasaki
    • 1
  • Takeshi Nagayasu
    • 1
  1. 1.Department of Surgical OncologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  2. 2.Second Department of Internal MedicineNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  3. 3.Department of RadiologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  4. 4.Department of SurgeryThe Japanese Red Cross Nagasaki Genbaku HospitalNagasakiJapan
  5. 5.Department of PathologyNagasaki University HospitalNagasakiJapan
  6. 6.Department of Internal MedicineTochigi Cancer CenterUtsunomiyaJapan
  7. 7.Clinical Oncology CenterNagasaki University HospitalNagasakiJapan

Personalised recommendations